logo
borderborderborderborderNews Roomborderborderborderborder
You are here - Home > News Room > Archive

Search News Room
go
Subscribe
Subscribe to the News Room email alert service.
subscribe

Contact
Investor/Shareholder/
Media Enquiries

T +612 9236 6065
F +612 9252 2192
email

Website Privacy Statement
Terms of Use
Site Map
Current
Archive
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
Media Contacts
Archive News print version

8 December 2000

Jacobs Lend Lease to Construct Biotech Plant for Making New Hepatitis C Drug in Singapore
JACOBS LEND LEASE TO CONSTRUCT BIOTECH PLANT FOR MAKING NEW HEPATITIS C DRUG IN SINGAPORE
8th December 2000

Singapore – Jacobs Lend Lease has been contracted by Schering-Plough, the American pharmaceutical company, to provide engineering, procurement and construction management services for a US$ 100 million biotech plant which will produce a new hepatitis C drug. The facility will be located on a 5 ha site next to Schering-Plough’s existing bulk manufacturing plant in Tuas.

Front-end engineering and detailed design will be shared between Jacobs Lend Lease offices in Dublin, Ireland, and Singapore, with Singapore responsible for the full implementation of the construction. Local techniques for structural and architectural elements will be applied and integrated with a high degree of clean room finishes, all complying to standards set by the United States Food and Drugs Administration (FDA) and the international specifications of Good Manufacturing Practice (cGMP).

The project involves the construction of a 4-storey building block spanning 65,000 sqm. and comprises areas for administration, laboratory, plant-room, production and warehouse. There will also be a utility block for chiller units, cooling tower, tank farm and plant facilities.

Mr John Nine, Corporate Vice-President of Schering-Plough said, “ The biotech plant gives us a second facility from a contingency standpoint. But it also gives us the ability to make more products, fitting right into our strategy of producing new drugs. We expect it to be completed in 3½ years’ time. ”

Mr Barry Mann, Managing Director of Jacobs Lend Lease added, “ We have a longstanding working relationship with Schering-Plough in Singapore, and are pleased to be involved in their expansion plans. By involving our international and local resources, we are integrating our expertise to ensure the successful completion of the project.”

Jacobs Lend Lease was formed in June 1999 jointly by Bovis Lend Lease and Jacobs Engineering, to focus on the fast growing pharmaceutical sector in Singapore. Total pharmaceutical projects under management exceed US$ 700 million.

media